Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure 

Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure 

Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

No results found.